Antibodies protect from infection, underpin successful vaccines and elicit therapeutic responses in otherwise untreatable cancers and autoimmune conditions. The human IgG2 isotype displays a unique capacity to undergo disulfide shuffling in the hinge region, leading to modulation of its ability to drive target receptor signaling (agonism) in a variety of important immune receptors, through hitherto unexplained molecular mechanisms. To address the underlying process and reveal how hinge disulfide orientation affects agonistic activity, we generated a series of cysteine to serine exchange variants in the hinge region of the clinically relevant monoclonal antibody ChiLob7/4, directed against the key immune receptor CD40. We report how agonisti...
Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, w...
Antibodies link antigen and immunological effector systems through the use of highly flexible linker...
We report two antibodies, scFv 13B1 and MAb PD1.37, against the hinge regions of LHR and TSHR, respe...
Antibodies protect from infection, underpin successful vaccines and elicit therapeutic responses in ...
SummaryMonoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer tre...
Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment ...
Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising th...
sults with ‘‘checkpoint blocker’ ’ mAbs designed to antagonize related protein (GITR), in clinical d...
ABSTRACT: In this communication we present the detailed disulfide structure of IgG2 molecules. The c...
The use of monoclonal antibodies (mAbs) in cancer therapy is now well-established and is revolutioni...
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as the...
The crystal structure of IgG1 b12 represents the first visualization of an intact human IgG with a f...
Immunoglobulins couple the recognition of invading pathogens with the triggering of potent effector ...
Immunoglobulins couple the recognition of invading pathogens with the triggering of potent effector ...
Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, w...
Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, w...
Antibodies link antigen and immunological effector systems through the use of highly flexible linker...
We report two antibodies, scFv 13B1 and MAb PD1.37, against the hinge regions of LHR and TSHR, respe...
Antibodies protect from infection, underpin successful vaccines and elicit therapeutic responses in ...
SummaryMonoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer tre...
Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment ...
Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and antagonists, which display promising th...
sults with ‘‘checkpoint blocker’ ’ mAbs designed to antagonize related protein (GITR), in clinical d...
ABSTRACT: In this communication we present the detailed disulfide structure of IgG2 molecules. The c...
The use of monoclonal antibodies (mAbs) in cancer therapy is now well-established and is revolutioni...
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as the...
The crystal structure of IgG1 b12 represents the first visualization of an intact human IgG with a f...
Immunoglobulins couple the recognition of invading pathogens with the triggering of potent effector ...
Immunoglobulins couple the recognition of invading pathogens with the triggering of potent effector ...
Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, w...
Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, w...
Antibodies link antigen and immunological effector systems through the use of highly flexible linker...
We report two antibodies, scFv 13B1 and MAb PD1.37, against the hinge regions of LHR and TSHR, respe...